The FAP Gene Support Group are pleased to announce that they have been invited by Tillotts Pharma to support its survey of Patients with 'FAP' (Familial Adenomatous Polyposis)

Tillotts Pharma would like to broaden its knowledge about FAP. They are interested to find out more about the burden and needs of patients in daily life. The purpose of this Questionnaire is to increase their knowledge FAP and to better understand the patient’s perspective.

If you are a FAP patient and are interested in participating in this survey, please review the Terms and Conditions below. If you are in agreement and wish to continue, the link to the survey is also found below.

The format is a web-based survey on the platform SmartSurvey

Terms and Conditions
This Questionnaire was commissioned by Tillotts Pharma AG ("Tillotts" or "we"). The purpose of this Questionnaire is to increase our knowledge of familial adenomatous polyposis ("FAP") and to better understand the patient's perspective. By proceeding with this Questionnaire you grant us the unrestricted right to use your Questionnaire responses for this purpose. You have been invited to participate in this Questionnaire through your Patient Organisation. Tillotts Pharma AG has not and will not receive any of your identifying information. Your participation in this Questionnaire is voluntary. You are free to choose not to participate. The online Questionnaire will take approximately 10 minutes. Your responses will be treated confidentially and we do not collect identifying information such as your name, email address or IP address. The answers to the Questionnaire do not need and should not contain information that will personally identify you - please do not include your name or any other identifying information in any of your responses. If you have any questions about the Questionnaire, please contact your Patient Organisation. By proceeding with this Questionnaire, you agree to the privacy policy and terms of use of SmartSurvey, the survey hosting platform.

The FAP Gene Support Group will receive a donation from Tillotts Pharma to cover their expenses.